NCT06741228Phase 3Active not recruiting

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

Study sponsor: Definium Therapeutics US, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-07-15Actual
Enrollment · participants214Actual
Source updated2026-09-25Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jul 2026. After: 15 Jul 2026.

Check registry source

· 1 field changed

Primary completion date changed

Before: May 2026. After: Jul 2026.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 200 participants (planned). After: 214 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview